Psychedelic Therapies Become New Biotech Hotspot Amid New Legitimacy
For decades, psychedelic therapy was only an experimental idea under research by organizations at academic institutions including Johns Hopkins. This changed in 2018 after life sciences company COMPASS Pathways plc (NASDAQ:CMPS) received Breakthrough Therapy Designation ... [Read]
Compass Pathways Leads the Way as the First Psychedelics Company to IPO on the Nasdaq
September 24, 2020 (MicroSmallCap via Comtex) — Last year may have been all about cannabis, but it’s clear that 2020 and beyond belongs to the psychedelic medicine market. Ever since Johnson & Johnson’s (NYSE:JNJ) ketamine-derived ... [Read]
Drug Candidates to Combat the Opioid Epidemic Have Begun Entering Clinical Trials
April 24, 2020 (MicroSmallCap via Comtex) — Opioid addiction has become the number one cause of accidental death in Canada and the United States for people under the age of 50. According to data from ... [Read]
Psychedelic-Derived Medicines Could Treat PTSD and ADHD | Companies are Positioning Themselves to Lead the Sector
After being stifled for decades by repressive drug laws and a stigma associating them with counterculture, research into psychedelic substances is finally being embraced by the government, corporations, and the medical community. In March, the ... [Read]